Phuturdex › Diseases › Autoimmune disease of the nervous system
Drugs in development · updated 30 October 2026
Autoimmune disease of the nervous system: drugs in development
As of 30 October 2026 there are 17 active clinical trials (recruiting or ongoing, phases I–III) on 21 drugs for autoimmune disease of the nervous system. 6 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| RiliprubartBIVV020 | III | 1 | NCT06290128 |
| ART5803 | II | 1 | NCT07093333 |
| CTX112 | I–II | 1 | NCT07804004 |
| CD20 | I | 1 | NCT07341828 |
| CTA313 | I | 1 | NCT07783269 |
| CD19 | Early I | 1 | NCT07337785 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| RituximabRuxience, Rituxan | III | 2 | NCT05834855 |
| DaratumumabDarzalex | III | 1 | NCT06867991 |
| OfatumumabKesimpta®, Arzerra® | III | 1 | NCT06867991 |
| Anti-Thymocyte Globulin | II | 1 | NCT00716066 |
| BortezomibVelcade, Bortezomib Hospira® | II | 1 | NCT03993262 |
| CarmustineBCNU, BiCNU | II | 1 | NCT00716066 |
| CytarabineAra-C, Cytosine Arabinoside | II | 1 | NCT00716066 |
| Efgartigimod IVEfgartigimod Alfa, Vyvgart® | II | 1 | NCT07822776 |
| EtoposideAvopef®, Etopophos Preservative Free® | II | 1 | NCT00716066 |
| InebilizumabUplizna® | II | 1 | NCT04372615 |
| MelphalanEvomela®, Hepzato® | II | 1 | NCT00716066 |
| MetforminRiomet Er®, Glumetza® | II | 1 | NCT05893225 |
| PrednisonePredinisone, Cortancyl | II | 1 | NCT00716066 |
| CyclophosphamideCyclophosphamid, Cytoxan | I | 3 | NCT06626919 |
| FludarabineFludara, FLUDARABIN | I | 3 | NCT06626919 |
Sorted by most advanced phase and number of active trials.
All 21 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Multiple sclerosis 93 drugs
- Myasthenia gravis 49 drugs
- Chronic progressive multiple sclerosis 39 drugs
- Relapsing-remitting multiple sclerosis 26 drugs
- Neuromyelitis optica 25 drugs
- Chronic inflammatory demyelinating polyradiculoneuropathy 23 drugs
- Autoimmune disease 94 drugs
- Giant cell arteritis 30 drugs
- Systemic lupus erythematosus 178 drugs
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease 9 drugs
- Optic neuritis 6 drugs
- Systemic scleroderma 77 drugs
Broader categories
- Immune System Diseases 54 drugs
- Nervous System Diseases 39 drugs
- Autoimmune disease 94 drugs
- Central nervous system disease 38 drugs
- Demyelinating disease 6 drugs
- Brain Diseases 23 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D020274 “Autoimmune Diseases of the Nervous System”.